Flumatinib mesylate Catalog No.:M9593-10 NSC-348884 also disrupts oligomer formation

NSC-348884 also disrupts oligomer formation and induces apoptosis in human cancer cells

Epub 2015 Mar 28

Formula: C22H30N2O2S

InChi: InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H

DGAT1-IN-3 (50 mg/kg

Flumatinib mesylate Catalog No.:M9593-10 NSC-348884 also disrupts oligomer formationFlumatinib, also known as HHGV678 , is a selective inhibitor of BCR ABL PDGFR KIT. Flumatinib is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML). Flumatinib effectively overcomes drug resistance of certain KIT mutants. Flumatinib mesylate can reduce the expression of C MYC, HIF 1 and VEGF in U266 cell line in a time and dose dependent manners. Product information CAS Number: 895519 91 2